IQV vs IDXX vs WAT
161 measures in 16 categories, one definition each, computed from filings and market data.
IQV56.4
IQVIA Holdings Inc.
Healthcare · Medical - Diagnostics & Research
$266.90 −1.49%$43.9B mkt cap
Score DNA
IDXX80.3
IDEXX Laboratories, Inc.
Healthcare · Medical - Diagnostics & Research
$560.36 +2.41%$44.1B mkt cap
Score DNA
WAT46.5
Waters Corporation
Healthcare · Medical - Diagnostics & Research
$436.95 −1.60%$42.9B mkt cap
Score DNA
Price, rebased to 100 three years ago
IQV IDXX WAT · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 0 | 1 | 0 |
| Last Congress purchase | — | 2026-09-25 | — |
| 13F net change in holders | +23 | −11 | +10 |
| ETFs adding shares, 30d | 1,126 | 1,337 | 1,174 |
| ETFs trimming, 30d | 1,089 | 1,036 | 1,004 |
| Net ETF funds, 30d | +37 | +301 | +170 |
Valuation
16 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| P/E (TTM) | 32.0x
35th
|
38.7x
65th
|
258.2x
100th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 2.76
62nd
|
2.68
38th
|
— |
| Price / sales | 2.6x
24th
|
9.7x
83rd
|
9.2x
79th
|
| Price / book | 7.1x
70th
|
27.4x
93rd
|
2.8x
33rd
|
| Price / tangible book | — | 38.5x
100th
|
— |
| Price / free cash flow | 16.8x
5th
|
35.3x
58th
|
107.7x
89th
|
| Price / operating cash flow | 15.6x
13th
|
32.3x
65th
|
78.0x
87th
|
| Enterprise value | $58.1B
93rd
|
$45.0B
79th
|
$47.6B
83rd
|
| EV / sales | 3.4x
31st
|
9.9x
79th
|
10.3x
83rd
|
| EV / EBITDA | 16.5x
24th
|
27.8x
71st
|
53.2x
81st
|
| EV / EBIT | 24.8x
29th
|
30.8x
59th
|
141.1x
100th
|
| EV / free cash flow | 22.2x
11th
|
36.0x
58th
|
119.5x
89th
|
| Earnings yield | 3.1%
79th
|
2.6%
62nd
|
0.4%
41st
|
| FCF yield | 5.9%
97th
|
2.8%
62nd
|
0.9%
41st
|
| Operating cash flow yield | 6.4%
90th
|
3.1%
48th
|
1.3%
31st
|
| Graham number (per share) | $81.95
71st
|
$79.71
65th
|
$76.74
59th
|
Profitability (TTM)
12 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Gross margin | 26.2%
14th
|
62.4%
69th
|
50.8%
45th
|
| EBITDA margin | 20.8%
62nd
|
35.5%
93rd
|
19.3%
59th
|
| Operating margin | 13.6%
62nd
|
32.0%
97th
|
8.0%
41st
|
| EBIT margin | 13.8%
62nd
|
32.1%
97th
|
7.3%
45th
|
| Net margin | 8.1%
52nd
|
25.0%
100th
|
3.6%
41st
|
| NOPAT margin | 11.4%
66th
|
25.6%
100th
|
6.4%
41st
|
| FCF margin | 15.4%
59th
|
27.5%
97th
|
8.6%
45th
|
| Operating cash flow margin | 16.6%
55th
|
30.0%
93rd
|
11.8%
38th
|
| R&D / revenue | 0.0%
0th
|
5.7%
38th
|
6.9%
48th
|
| SG&A / revenue | 12.1%
10th
|
24.7%
34th
|
26.1%
45th
|
| Stock comp / revenue | 1.6%
36th
|
— | 1.6%
32nd
|
| Effective tax rate | 15.7%
24th
|
20.0%
48th
|
19.1%
45th
|
Returns on capital
11 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| ROE (on average equity) | 23.0%
81st
|
74.2%
96th
|
1.9%
41st
|
| ROA | 4.7%
59th
|
33.7%
100th
|
1.1%
41st
|
| ROIC | 9.6%
69th
|
46.5%
93rd
|
1.5%
38th
|
| ROCE | 11.1%
79th
|
67.9%
97th
|
1.5%
41st
|
| Return on tangible assets | 8.0%
69th
|
43.2%
100th
|
2.3%
41st
|
| Cash ROIC (OCF / invested capital) | 13.9%
62nd
|
54.5%
93rd
|
2.8%
28th
|
| Gross profitability (GP / assets) | 14.9%
28th
|
82.6%
97th
|
9.5%
10th
|
| ROIC, 3-yr average | 7.3%
79th
|
35.4%
96th
|
12.4%
88th
|
| ROIC, 5-yr average | 7.6%
71st
|
43.0%
96th
|
25.2%
92nd
|
| ROE, 5-yr average | 21.1%
84th
|
81.9%
96th
|
68.1%
92nd
|
| Incremental ROIC | 96.4%
81st
|
— | -1.4%
52nd
|
Growth
17 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Revenue growth (TTM YoY) | 8.2%
54th
|
12.8%
68th
|
52.5%
100th
|
| Revenue growth (QoQ) | 5.2%
28th
|
6.6%
41st
|
29.8%
93rd
|
| Revenue CAGR, 3 yr | 5.0%
52nd
|
9.0%
63rd
|
15.8%
78th
|
| Revenue CAGR, 5 yr | 5.6%
48th
|
8.4%
52nd
|
11.7%
63rd
|
| Gross profit CAGR, 3 yr | -4.5%
19th
|
10.5%
70th
|
10.4%
67th
|
| Operating income CAGR, 3 yr | 7.7%
53rd
|
11.7%
73rd
|
-24.3%
0th
|
| Net income growth (TTM YoY) | 11.2%
44th
|
15.6%
56th
|
-74.9%
0th
|
| Net income CAGR, 3 yr | 7.9%
67th
|
12.9%
92nd
|
-37.3%
8th
|
| EPS growth (TTM YoY) | 14.2%
44th
|
16.1%
56th
|
-84.7%
0th
|
| EPS CAGR, 3 yr | 11.6%
83rd
|
14.4%
92nd
|
-47.1%
0th
|
| EPS CAGR, 5 yr | 21.2%
86th
|
11.0%
79th
|
-30.8%
0th
|
| FCF growth (TTM YoY) | 30.0%
72nd
|
61.5%
89th
|
-35.7%
6th
|
| FCF CAGR, 3 yr | 18.2%
71st
|
27.5%
86th
|
1.0%
21st
|
| Operating cash flow CAGR, 3 yr | 7.9%
47th
|
22.4%
71st
|
-1.3%
18th
|
| Book value CAGR, 3 yr | 5.9%
64th
|
15.3%
88th
|
127.9%
100th
|
| Dividend CAGR, 3 yr | — | — | — |
| Sustainable growth rate | 23.0%
69th
|
74.2%
94th
|
1.9%
0th
|
Margin history & stability
7 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Gross margin, 3-yr average | 31.3%
21st
|
61.5%
75th
|
56.5%
57th
|
| Operating margin, 3-yr average | 13.6%
64th
|
30.6%
96th
|
20.8%
82nd
|
| Net margin, 3-yr average | 8.5%
68th
|
23.9%
100th
|
15.3%
82nd
|
| FCF margin, 3-yr average | 13.4%
57th
|
22.9%
96th
|
16.1%
68th
|
| Revenue stability (0-1) | 0.98
93rd
|
0.97
89th
|
0.56
25th
|
| Earnings stability (0-1) | 0.64
75th
|
0.87
96th
|
0.49
57th
|
| Margin stability (0-1) | 0.89
43rd
|
0.98
86th
|
0.94
54th
|
Liquidity (latest quarter)
7 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Cash & short-term investments | $2.1B
93rd
|
$196.9M
21st
|
$539.0M
52nd
|
| Net cash (− = net debt) | −$14.2B
7th
|
−$899.1M
48th
|
−$4.7B
17th
|
| Working capital | −$2.6B
0th
|
$221.8M
24th
|
$2.1B
90th
|
| Current ratio | 0.71
0th
|
1.17
14th
|
1.86
45th
|
| Quick ratio | 0.71
0th
|
0.87
10th
|
1.29
28th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.24
21st
|
0.15
7th
|
0.22
14th
|
| Defensive interval (days) | 928 days
86th
|
247 days
10th
|
464 days
48th
|
Leverage & solvency (latest quarter)
13 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Total debt | $16.2B
93rd
|
$1.1B
45th
|
$5.3B
83rd
|
| Debt / equity | 2.63
96th
|
0.68
63rd
|
0.35
37th
|
| Net debt / equity | 2.29
96th
|
0.56
74th
|
0.31
52nd
|
| Debt / assets | 54.4%
90th
|
31.8%
55th
|
21.2%
31st
|
| Debt / capital | 72.5%
93rd
|
40.5%
61st
|
25.7%
36th
|
| Debt / EBITDA | 4.60
76th
|
0.68
10th
|
5.87
81st
|
| Net debt / EBITDA | 4.01
81st
|
0.56
19th
|
5.26
90th
|
| Interest coverage (EBIT / interest) | 3.0x
52nd
|
37.4x
92nd
|
2.4x
44th
|
| Cash interest coverage | 3.7x
28th
|
35.0x
88th
|
4.0x
32nd
|
| Debt payback (years of OCF) | 5.8 yrs
78th
|
0.8 yrs
13th
|
9.6 yrs
91st
|
| Liabilities / assets | 78.9%
90th
|
53.2%
62nd
|
38.6%
31st
|
| IS credit model rating | BB | AAA | BBB |
| Implied credit spread (bps) | 475
76th
|
50
0th
|
275
66th
|
Efficiency
11 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Asset turnover | 0.58
55th
|
1.34
97th
|
0.32
21st
|
| Fixed asset turnover | 19.96
100th
|
5.32
79th
|
2.50
21st
|
| Inventory turnover | — | 4.4
32nd
|
2.4
0th
|
| Receivables turnover | 7.1
66th
|
7.3
72nd
|
3.4
3rd
|
| Days sales outstanding | 52 days
34th
|
50 days
28th
|
107 days
97th
|
| Days inventory outstanding | — | 84 days
68th
|
153 days
100th
|
| Days payables outstanding | 102 days
100th
|
26 days
31st
|
77 days
90th
|
| Cash conversion cycle (days) | −51 days
0th
|
108 days
76th
|
183 days
100th
|
| Capex / revenue | 1.2%
7th
|
2.6%
31st
|
3.3%
41st
|
| Capex / depreciation | 0.17
10th
|
0.76
62nd
|
0.27
14th
|
| Operating expense ratio | 21.3%
17th
|
29.1%
31st
|
49.8%
55th
|
Cash flow & earnings quality
7 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Operating cash flow / net income | 2.05
82nd
|
1.20
24th
|
3.31
94th
|
| FCF / net income | 1.90
82nd
|
1.10
41st
|
2.40
94th
|
| FCF / operating cash flow | 92.7%
91st
|
91.4%
87th
|
72.5%
48th
|
| Capex / operating cash flow | 7.3%
9th
|
8.6%
13th
|
27.5%
52nd
|
| Accruals ratio | -4.9%
41st
|
-6.7%
31st
|
-2.6%
76th
|
| Sloan accruals ratio | -8.7%
7th
|
-2.1%
41st
|
5.0%
79th
|
| Earnings quality score (0-1) | 1.00
24th
|
0.75
0th
|
1.00
24th
|
Scores & forensic checks
15 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| IS score | 56
55th
|
80
97th
|
47
41st
|
| IS profitability | 45
59th
|
99
100th
|
16
21st
|
| IS growth | 55
46th
|
68
79th
|
40
25th
|
| IS value | 41
52nd
|
30
14th
|
35
34th
|
| IS momentum | 82
68th
|
85
82nd
|
70
43rd
|
| IS risk (safety) | 50
21st
|
100
62nd
|
80
38th
|
| IS quality | 59
41st
|
94
100th
|
60
45th
|
| IS balance sheet | 21
21st
|
70
72nd
|
44
41st
|
| IS earnings quality | 70
59th
|
69
48th
|
70
55th
|
| IS cash flow | 71
79th
|
89
93rd
|
43
41st
|
| Piotroski F-score (0-9) | 7
59th
|
9
100th
|
5
28th
|
| Altman Z-score | 1.9
24th
|
19.6
90th
|
3.2
41st
|
| Beneish M-score | −2.69
25th
|
−2.71
21st
|
−0.61
96th
|
| Ohlson O-score | −6.50
69th
|
−9.27
17th
|
−8.62
38th
|
| IS credit score | 44
24th
|
96
100th
|
58
34th
|
Size (TTM)
8 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| Market cap | $43.9B
83rd
|
$44.1B
86th
|
$42.9B
79th
|
| Revenue | $17.0B
93rd
|
$4.6B
72nd
|
$4.6B
76th
|
| EBITDA | $3.5B
93rd
|
$1.6B
79th
|
$895.8M
66th
|
| Net income | $1.4B
90th
|
$1.1B
86th
|
$166.1M
55th
|
| Free cash flow | $2.6B
93rd
|
$1.3B
83rd
|
$398.5M
55th
|
| Total assets | $29.9B
93rd
|
$3.4B
52nd
|
$24.8B
90th
|
| Shareholders' equity | $6.2B
72nd
|
$1.6B
52nd
|
$15.2B
93rd
|
| Employees | 94,000
97th
|
11,000
66th
|
7,900
55th
|
Price performance
9 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| 1 day | −1.5% | +2.4% | −1.6% |
| 1 week | +2.7% | +8.2% | +0.8% |
| 1 month | −0.9% | +10.6% | +1.7% |
| 3 months | +30.9% | −0.6% | +22.2% |
| 6 months | +51.3% | −4.9% | +33.3% |
| Year to date | +18.5% | −16.4% | +14.4% |
| 1 year | +31.4% | −12.3% | +31.5% |
| 3 years, cumulative | +30.5% | +25.7% | +64.2% |
| 5 years, cumulative | +10.2% | −9.2% | +27.3% |
Technicals
4 measures| Measure | IQV | IDXX | WAT |
|---|---|---|---|
| RSI 14 | 54.9 | 66.0 | 55.9 |
| From 52-week high | −3.8% | −27.2% | −3.9% |
| From 52-week low | +72.8% | +11.9% | +54.5% |
| Beta | 1.17 | 1.55 | 1.15 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17